PFE | Weekly | Haru Insights

Pfizer announced a strategic review of future investments in Germany due to escalating drug pricing reforms, signaling potential shifts in its European R&D and operational footprint.
Pfizer entered a phase II collaboration with Corcept Therapeutics to evaluate Xtandi in combination therapy, expanding its oncology pipeline despite limited near-term commercial impact.

Pfizer’s sustained organic growth in non-COVID franchises—Eliquis, Padcev, and Lorbrena—proves its ability to transition beyond pandemic revenue, reinforcing a resilient core business.
The company’s leadership in high-growth areas like oncology and rare diseases, backed by alliances such as the Innovent deal, underscores a credible innovation engine for future value creation.
Inclusion in Cboe’s extended-hours trading on the C1 exchange reflects strong institutional liquidity and market confidence, signaling enduring investor trust amid sector volatility.
The commercialization of next-gen assets like SSGJ-707 and expanded focus on hematology and solid tumors highlight a diversified, forward-looking growth platform beyond legacy products.
Strategic collaborations, including the phase II Xtandi partnership, demonstrate proactive pipeline expansion in oncology, enhancing long-term therapeutic depth and competitive positioning.

Pfizer Inc. (PFE)[Tv]